ARCT News and Press, Arcturus Therapeutics Ltd. From 07/26/21

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...

Mario13/E+ via Getty Images Arcturus wins new bullish call at Cantor on experimental COVID-19 shot Arcturus Therapeutics (ARCT) has added ~1.3% in the pre-market after Cantor Fitzgerald initiated its coverage with an overweight recommendation highlighting the company’s effort...

carmengabriela/iStock Editorial via Getty Images The manufacturers of messenger-RNA-based COVID-19 vaccines are trading lower after a safety group of the U.S. Centers for Disease Control and Prevention ((CDC)) said there is a “likely association” between a rare heart inflammatio...

Merger news and drug development moved some stocks in Monday's pre-market action. Raven (RAVN) and Rafael Holdings (RFL) advanced on merger deals. Meanwhile, MediciNova (MNOV) and Theravance Bio (TBPH) moved in opposite directions on the release of new clinical trial data.The return of travel...

This article will explain some of the science that Moderna has developed behind their mRNA-based vaccines, including the COVID-19 vaccine. Moderna's platform research investments, digital backbone + manufacturing plants, and structured data collection are competitive advantages. M...

Arcturus Therapeutics Holdings (ARCT) has been granted an exclusive license of an enzyme for an RNA polymerase (RNApol) by synthetic biology company Primordial Genetics.The enzyme was discovered by Primordial to meet the challenge of manufacturing high-quality, long RNAs for therape...

Primordial Genetics Grants Arcturus Therapeutics Exclusive License of an RNA Polymerase for Human and Animal Therapeutics PR Newswire SAN DIEGO , June 2, 2021 /PRNewswire/ -- Primordial Genetics ("Primordial"), a synthetic biology company developing enzymatic pro...

Arcturus Therapeutics Holdings, Inc. (ARCT) Q1 2021 Earnings Conference Call May 10, 2021 4:30 PM ET Company Participants Neda Safarzadeh – Head of Investor Relations, Public Relations and Marketing Joseph Payne – President and Chief Executive Officer Andy Sassine – Chief...

Arcturus Therapeutics (ARCT): Q1 GAAP EPS of -$2.15 misses by $0.87.Revenue of $2.13M (-19.6% Y/Y) misses by $0.39M.The Company’s cash balance totaled $466.9 million as of March 31, 2021, compared to cash and cash equivalents of $463.0 million at December 31, 2020. Based on our current...

ARCT-021 Phase 2 interim data showed favorable safety profile and greater than 90% seroconversion after a single dose; data supports advancement into Phase 3 In negotiations with multiple regulatory authorities regarding ARCT-021 Phase 3 study program Continued progres...